VEGF TrapR1R2 suppresses experimental corneal angiogenesis

European Journal of Ophthalmology

Volumn 20, Issue 1, 2010, Pages 48-54

  Oliveira, Hailton B ^a   Sakimoto, Tohru ^a   Javier, Joel A D ^a   Azar, Dimitri T ^a,b   Wiegand, Stanley J ^c   Jain, Sandeep ^a,b   Chang, Jin Hong ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c REGENERON PHARMACEUTICALS INC   (United States)

Author keywords

Angiogenesis; bFGF; Cornea

Indexed keywords

AFLIBERCEPT; BASIC FIBROBLAST GROWTH FACTOR; IMMUNOGLOBULIN FC FRAGMENT; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORNEA CELL; CORNEA NEOVASCULARIZATION; CORNEA STROMA; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIUM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 76649130947     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.1177/112067211002000106     Document Type: Article

References (25)

1. Azar DT. Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc 2006; 104: 264-302.
2. Ambati BK, Nozaki M, Singh N, et al. Corneal avascularity is due to soluble VEGF receptor-1. Nature 2006; 443: 993-7.
3. Cursiefen C, Chen L, Saint-Geniez M, et al. Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision. Proc Natl Acad Sci USA 2006; 103: 11405-10.
4. Maharaj AS, Saint-Geniez M, Maldonado AE, D'Amore PA. Vascular endothelial growth factor localization in the adult. Am J Pathol 2006; 168: 639-48.
5. Chappelow AV, Kaiser PK. Neovascular age-related macular degeneration: potential therapies. Drugs 2008; 68: 1029-36.
6. Rudge JS, Holash J, Hylton D, et al. Inaugural article: VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc Natl Acad Sci USA 2007; 104: 18363-70.
7. Velazquez OC. Angiogenesis and vasculogenesis: inducing the growth of new blood vessels and wound healing by stimulation of bone marrow-derived progenitor cell mobilization and homing. J Vasc Surg 2007; 45(Suppl A); A39-47.
8. Jakobsson L, Kreuger J, Claesson-Welsh L. Building blood vesselsóstem cell models in vascular biology. J Cell Biol 2007; 177: 751-5.
9. Eming SA, Brachvogel B, Odorisio T, Koch M. Regulation of angiogenesis: wound healing as a model. Prog Histochem Cytochem 2007; 42: 115-70.
10. Shibuya M, Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 2006; 312: 549-60.
11. Motiejunaite R, Kazlauskas A. Pericytes and ocular diseases. Exp Eye Res 2008; 86: 171-7.
12. Ejaz S, Chekarova I, Ejaz A, Sohail A, Lim CW. Importance of pericytes and mechanisms of pericyte loss during diabetes retinopathy. Diabetes Obes Metab 2008; 10: 53-63.
13. Yan W, Bentley B, Shao R. Distinct angiogenic mediators are required for basic fibroblast growth factor- and vascular endothelial growth factor-induced angiogenesis: the role of cytoplasmic tyrosine kinase c-Abl in tumor angiogenesis. Mol Biol Cell 2008; 19: 2278-88.
14. Lee IY, Kim J, Ko EM, Jeoung EJ, Kwon YG, Choe J. Interleukin-4 inhibits the vascular endothelial growth factor- and basic fibroblast growth factor-induced angiogenesis in vitro. Mol Cells 2002; 14: 115-21.
15. Poltorak Z, Cohen T, Sivan R, et al. VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix. J Biol Chem 1997; 272: 7151-8.
16. Folkman J, Shing Y. Control of angiogenesis by heparin and other sulfated polysaccharides. Adv Exp Med Biol 1992; 313: 355-64.
17. Ley CD, Olsen MW, Lund EL, Kristjansen PE. Angiogenic synergy of bFGF and VEGF is antagonized by angiopoietin-2 in a modified in vivo Matrigel assay. Microvasc Res 2004; 68: 161-8.
18. Seghezzi G, Patel S, Ren CJ, et al. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. J Cell Biol 1998; 141: 1659-73.
19. Kenyon BM, Voest EE, Chen CC, Flynn E, Folkman J, D'Amato RJ. A model of angiogenesis in the mouse cornea. Invest Ophthalmol Vis Sci 1996; 37: 1625-32.
20. Kure T, Chang JH, Kato T, et al. Corneal neovascularization after excimer keratectomy wounds in matrilysin-deficient mice. Invest Ophthalmol Vis Sci 2003; 44: 137-44.
21. Miquerol L, Gertsenstein M, Harpal K, Rossant J, Nagy A. Multiple developmental roles of VEGF suggested by a LacZtagged allele. Dev Biol 1999; 212: 307-22.
22. Cursiefen C. Immune privilege and angiogenic privilege of the cornea. Chem Immunol Allergy 2007; 92: 50-7.
23. Onguchi T, Han KY, Chang JH, Azar DT. Membrane type-1 matrix metalloproteinase potentiates basic fibroblast growth factor-induced corneal neovascularization. Am J Pathol 2009; 174: 1564-71.
24. Cursiefen C, Cao J, Chen L, et al. Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci 2004; 45: 2666-73.
25. Chang LK, Garcia-Cardena G, Farnebo F, et al. Dose-dependent response of FGF-2 for lymphangiogenesis. Proc Natl Acad Sci USA 2004; 101: 11658-63.